Clinical Trial Update: Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma [Phase 4]

View source ↗

Summary

A Phase 4 study evaluated whether omalizumab improves the tolerability of specific immunotherapy in patients with persistent allergic asthma; results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Asthma

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Novartis | Conditions: Allergic Asthma | Phase 4 | Status: COMPLETED | Results posted: 2011-05-16